UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K
CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **January 11, 2021**

Aethlon Medical, Inc.
(Exact name of registrant as specified in its charter)

Nevada	**001-37487**	**13-3632859**
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

9635 Granite Ridge Drive, Suite 100 **San Diego, California** (Address of principal executive offices)	**92123** (Zip Code)

Registrant's telephone number, including area code: 858-459-7800

Not applicable
(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol	Name of each exchange on which registered
Common Stock	AEMD	The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On January 11, 2021, members of management ofAethlon Medical, Inc. (the "Company") will begin using the investor presentation attached as Exhibit 99.1 to this report in various meetings and industry conferences with investors, securities analysts and others. The Corporate Presentation is available under the "Investors" section of the Company's website.

The information in this Item 7.01 of this Current Report on 8-K (including Exhibit 99.1) is furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information shall not be deemed incorporated by reference into any other filing with the Securities and Exchange Commission made by the Company, whether made before or after today's date, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific references in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	**Description**
99.1	Corporate presentation, dated January 11, 2021

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Aethlon Medical, Inc.

Dated: January 11, 2021

By: /s/ James B. Frakes
James B. Frakes
Chief Financial Officer

Exhibit 99.1

aethlon MEDICAL, INC.

NASDAQ: AEMD

Investor Presentation

January 2021

FORWARD LOOKING STATEMENTS

This investor presentation contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including, without limitation: the ability to enroll patients in the Early Feasibility Studies; the ability to successfully complete the Early Feasibility Studies and achieve the endpoints for the studies, or any future studies with the Hemopurifier or to successfully develop and commercialize the Hemopurifier; the ability to demonstrate the removal of exosomes with the Hemopurifier; the potential synergistic use of the Hemopurifier with chemotherapy, immunotherapy and targeted agents; the ability to demonstrate the removal of SARS-CoV-2/COVID-19 glycoproteins with the Hemopurifier; the potential initiation of a SARS-CoV-2 clinical trial; the ability to establish collaborations and to raise capital; and financial strength and guidance. These statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to: the risks associated with Covid-19 and other pandemic risks; the timing and success of Aethlon's studies and trials; our ability to enroll patients in our studies and trials on a timely basis, or at all; the Early Feasibility Studies and potential safety and other complications thereof; the ability to obtain regulatory approval within the timeframe expected, or at all; complications associated with product development and commercialization activities; the scope, progress and expansion of developing Aethlon's product candidates; the size and growth of the market(s) therefor and the rate and degree of market acceptance thereof vis-à-vis alternative therapies; and Aethlon's ability to attract or retain key management, members of the board of directors and personnel. In light of these risks and uncertainties, and other risks and uncertainties that are described in the Risk Factors section of Aethlon's Form 10-Q filed with the SEC on October 28, 2020, subsequent 10-Q filings, and other filings that Aethlon makes with the SEC from time to time (which are available at http://www.sec.gov), the events and circumstances discussed in such forward-looking statements may not occur, and Aethlon's actual results could differ materially and adversely from those anticipated or implied thereby. Any forward-looking statements speak only as of the date of this presentation and are based on information available to Aethlon as of the date of this presentation.

The Aethlon Hemopurifier®

- Two FDA "Breakthrough Device" designations
  - Safety in over 150 patient treatments in human trials or emergency use
  - Proprietary mechanism of action
  - Clears life-threatening glycosylated viruses
  - Designed to clear cancer promoting exosomes

Aethlon Medical

- Hemopurifier® in human trials for oncology and viral diseases
- Experienced management team
- Strong cash position
- Non-dilutive NCI funding for multiple programs
- Based in San Diego

Hemopurifier® Design



- Hollow-fiber plasma separator filled with proprietary affinity resin in the extra-capillary space outside of cartridge fibers
- Captures enveloped viral pathogens and exosomes in circulating blood based on size and glycosylation



- Used with either dialysis or CRRT machine. Proprietary pump closed system being evaluated
- Capture of glycosylated particles contrasts with clearance of inflammatory mediators by other extracorporeal cartridges

Pipeline



Hemopurifier® Programs

Oncology

- Clearance of cancer promoting exosomes
- Potentially synergistic with chemotherapy, immunotherapy, targeted agents
- Multiple potential clinical targets:
  - Breast, head and neck, gastrointestinal, melanoma, other solid tumors
- Well characterized markets, development pathways & endpoints
- Early feasibility study (EFS) in head and neck cancer initiated with first patient treatment at University of Pittsburgh Medical Center in December 2020

Why Exosomes?

- Key mediators in cell communication and potent drivers in healing and repair
- They shed from both normal and malignant cells
- Primary means of intra-cellular communication
- Tumor derived exosomes (TEX)—released by tumor cells that promote:
  - Metastasis, chemotherapy/targeted therapy resistance, immune suppression
- There is no existing treatment for depleting tumor-derived exosomes
- Also involved in viral disease – inflammation, coagulopathy
- *Hemopurifier® is the first candidate capable of clearing exosomes*

Tumor-derived Exosomes (TEX) Being Released by Tumor cell



National Cancer Institute Studies

- Phase I contract from NCI — Completed
  "Device Strategy for Differential Isolation of Oncosomes and Non-Malignant Exosomes"

- NCI SBIR Grant — Completed
  "The Hemopurifier® Device for Targeted Removal of Breast Cancer Exosomes from the Blood Circulation"

- Phase II NCI SBIR Contract — September 2019
  - $1.8 million over 2 years

  "Technologies for Differential Isolation of Exosomes and Oncosomes"

- NIDCR RO1 — July 2020
  - Collaboration with University of Pittsburgh, MGH, UHawaii
  - $3.5 million over 5 years

  "Depleting exosomes to improve responses to immune therapy in head and neck squamous cell carcinoma"

EFS in Head and Neck Cancer

- NCT #04453046
- University of Pittsburgh Hillman Cancer Center
- 10-12 subjects with advanced or metastatic HNSSC
- Combination with pembrolizumab (Keytruda®)
  - Keytruda approved June 2019 in front line setting
- 4-hour Hemopurifier treatment immediately prior to Keytruda
- Endpoints: Safety, exosome clearance and characterization
  - ORR, PFS, OS
- First patient treated in December 2020

Hemopurifier® Treatment of Viral Infections

- Demonstrated clearance of multiple different viruses *in vitro*
  - HIV, dengue, West Nile, influenza, Ebola, herpes, MERS
- Safety and viral clearance in four human clinical trials in HCV
- Over 120 successful applications in humans with HCV with no safety issues
- Single patient treatments in Ebola and HIV
  - Open protocol for emergency Use in US and Canada for Ebola
  - IDE Supplement for COVID-19 - June 2020

Hemopurifier® Treatment of SARS-CoV-2/COVID-19

- Circulating virus correlates with cytokine levels and poor outcome
- Hemopurifier has been shown to clear MERS, another coronavirus
- Clears SARS-CoV-2/COVID-19 glycoproteins based on in vitro experiments
- IDE supplement for COVID-19 approved June 17, 2020
- New Feasibility Study starting
- Approved for 20 sites—40 patients in total
- ICU patients with severe or life-threatening symptoms and central IV access
- Patient already treated under Single Patient Emergency Use regulations

Aethlon Medical Senior Management Team

Charles J. Fisher, Jr., M.D., FACP, FCCP, FCCM, Chief Executive Officer

- Academic & Industry thought leader in sepsis & inflammation
- Head of critical care—Cleveland Clinic
- 35 years industry development experience
- Senior executive—Lilly, Abbott, Cardiome

James B. Frakes, MBA, Senior VP & Chief Financial Officer

- 29 years public company CFO experience
- Investment banking & venture capital

Steven LaRosa, MD, Chief Medical Officer (CMO)

- 25 Years Infectious Diseases, Critical Care, Coagulation, Inflammation, Infectious Diseases, Cancer

Guy Cipriani, MBA, Senior VP & Chief Business Officer

- 20 Years experience in public companies as CBO

Thomas L. Taccini, VP Manufacturing & Product Development

- Over 35 years experience in engineering
- Product development and quality systems

Strong Cash Position

- September 30, 2020 Company's cash balance was approximately $14.5 million
- No debt
- NASDAQ: AEMD ~12.1 million shares outstanding

Upcoming News 2020-2021

Aethlon Hemopurifier®

- IDE supplement approved for SARS-CoV-2/COVID-19 ✔
- Emergency treatment of SARS-CoV-2/COVID-19 patients ✔
- EFS initiated for head and neck cancer and first patient treated ✔

- Expected News:
- Initiation of SARS-CoV-2 trial
- Early clinical data from EFS trials
- Proof of concept for other solid tumors

Summary

- Unique Hemopurifier® blood purification device
- Two FDA Breakthrough Designations
- Multiple therapeutic targets in cancer and viral disease
- Management team with well over 100 years healthcare experience

9635 Granite Ridge Drive, Suite 100
San Diego, California 92123
858.459.7800
Nasdaq: AEMD
www.AethlonMedical.com

This presentation may contain predictions, estimates, and other forward looking statements that involve risks and uncertainties, including whether and when our products are successfully developed and introduced; market acceptance of the Aethlon Hemopurifier® and other product offerings; regulatory delays, manufacturing delays, and other risks detailed in our SEC filings, which are accessible at www.sec.gov or on our website: www.AethlonMedical.com